ReviewWorld journal of gastroenterology2019
Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Insights into the Biochemical and Immune Mechanisms in Drug-Induced Liver Injury Pathogenesis.Chemical research in toxicology · 2026Review
- COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature.Pathogens (Basel, Switzerland) · 2022Review
- Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.Journal of clinical and translational hepatology · 2022Review
- Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19.Pathogens (Basel, Switzerland) · 2022Review
- Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients.Biomedicines · 2022Article
- Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases.Journal of clinical medicine · 2021Review
- Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.World journal of clinical cases · 2021Review
- Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment.Journal of personalized medicine · 2021Review
- Hepatitis B virus reactivation during temozolomide administration for malignant glioma.International journal of clinical oncology · 2021Article
- Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.Frontiers in immunology · 2021Article
- HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies.Frontiers in oncology · 2021Review
- Gastroenterological complications in kidney transplant patients.Open medicine (Warsaw, Poland) · 2020Review
- Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case.Open medicine (Warsaw, Poland) · 2020Article
- Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.Journal for immunotherapy of cancer · 2019Article
- Review
- Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management.Open medicine (Warsaw, Poland) · 2019Article
- Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases.Open medicine (Warsaw, Poland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.